(Q42923011)

11 November 2017

title

Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir (English)

1 reference

11 November 2017

Huldrych F Günthard

3

0 references

Matthias Cavassini

object named as

Matthias Cavassini

7

0 references

Sabine Yerly

8

object named as

Sabine Yerly

1 reference

11 November 2017

5

Bernard Hirschel

1 reference

11 November 2017

Laurent Arthur Decosterd

6

object named as

Laurent-Arthur Decosterd

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20802298

3 July 2024

author name string

Christine Gutmann

1

1 reference

11 November 2017

Alexia Cusini

2

1 reference

11 November 2017

Christoph Fux

4

1 reference

11 November 2017

Swiss HIV Cohort Study (SHCS)

10

1 reference

11 November 2017

Pietro L. Vernazza

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20802298

3 July 2024

language of work or name

English

0 references

publication date

1 September 2010

1 reference

11 November 2017

24 September 2010

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20802298

3 July 2024

number of pages

8

1 reference

based on heuristic

inferred from page(s)

published in

AIDS

1 reference

11 November 2017

volume

24

1 reference

11 November 2017

issue

15

1 reference

11 November 2017

page(s)

2347-2354

1 reference

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

11 November 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833DB9A1

Lipids, metabolic syndrome, and risk factors for future cardiovascular disease among HIV-infected patients

3 July 2024

2

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833DB9A1

Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team

3 July 2024

3

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833DB9A1

Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study).

3 July 2024

4

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833DB9A1

The role of compartment penetration in PI-Monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial

3 July 2024

5

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833DB9A1

Determinants of HIV-1 shedding in the genital tract of women.

3 July 2024

6

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833DB9A1

Cell-associated HIV-1 RNA in blood as indicator of virus load in lymph nodes. The Swiss HIV Cohort Study

3 July 2024

7

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833DB9A1

Decay of cell-associated HIV-1 DNA correlates with residual replication in patients treated during acute HIV-1 infection

3 July 2024

8

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833DB9A1

Transmission of antiretroviral-drug-resistant HIV-1 variants

3 July 2024

9

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833DB9A1

Update of the Drug Resistance Mutations in HIV-1.

3 July 2024

10

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833DB9A1

Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis.

3 July 2024

11

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833DB9A1

Ritonavir boosted indinavir treatment as a simplified maintenance "mono"-therapy for HIV infection

3 July 2024

12

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833DB9A1

Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression

3 July 2024

13

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833DB9A1

Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV.

3 July 2024

14

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833DB9A1

Unsuspected HIV infection in patients presenting with acute meningitis

3 July 2024

15

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833DB9A1

Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance

3 July 2024

16

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833DB9A1

Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine

3 July 2024

17

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833DB9A1

Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine

3 July 2024

18

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833DB9A1

Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression.

3 July 2024

19

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833DB9A1

3 July 2024

Identifiers

1 reference

11 November 2017

1 reference